Manageable Divestiture Likely in the Works for NxStage/Fresenius Merger

Register to receive a free US Market Report Suite for Dialysis Device and Concentrates report synopsis and brochure

Antitrust attorneys working with third parties told CTFN that a divestiture of NxStage’s bloodline tubing unit is being discussed as a condition in closing its $2 billion acquisition by Fresenius.

“NxStage is DaVita’s longstanding and preferred bloodline tubing vendor,” one attorney said. “DaVita directly competes with Fresenius in the in-clinic dialysis space. This unit will have to go.”

A divestiture of the smaller of the two firm’s units will almost certainly be a requirement, with the line going to a party other than Baxter, said a second attorney working with a third party. “There may be ancillary issues concerning R&D and other assets in this area, but I suspect the parties could put together a package that would work either for one of the smaller incumbents or a new entrant.”

This article was originally published by CTFN M&A Reporting, to read more please visit

For Further Information
More on the dialysis device market in the US can be found in a series of reports published by iData Research entitled the US Market Report Suite for Dialysis Devices and Concentrates. The suite covers reports on the following markets: hemodialysis and peritoneal dialysis machines, dialysis catheters, dialyzers, dialyzer reprocessing machines, hemodialysis bloodline and tubing sets, AV fistula needles, AV access grafts, declotting devices, introducer sheaths and guidewires and water treatment systems.

Reports provide a comprehensive analysis including units sold, procedure numbers, market value, forecasts, as well as detailed competitive market shares and analysis of major players’ success strategies in each market and segment. To find out more about dialysis device market data or procedure data, register online or email us at for a US Market Report Suite for Dialysis Device and Concentrates brochure and synopsis.

Leave a Reply